Factors Associated With Socioeconomic Disparities in Breast Reconstruction: Perspectives of Wisconsin Surgeons.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 461, doi. 10.1016/j.clbc.2023.03.010
- By:
- Publication type:
- Article
Works matching IS 15268209 AND DT 2023 AND VI 23 AND IP 4
Results: 15
1
2
Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 454, doi. 10.1016/j.clbc.2023.03.009
- By:
- Publication type:
- Article
3
Mild Cryotherapy for Prevention of Paclitaxel-Induced Nail Toxicity in Breast Cancer Patients: A Phase H Single-Arm Clinical Trial.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 447, doi. 10.1016/j.clbc.2023.03.004
- By:
- Publication type:
- Article
4
Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 436, doi. 10.1016/j.clbc.2023.03.002
- By:
- Publication type:
- Article
5
The Effects of the COVID-19 Pandemic on Mastectorny Outcomes for Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 431, doi. 10.1016/j.clbc.2023.02.010
- By:
- Publication type:
- Article
6
Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 423, doi. 10.1016/j.clbc.2023.02.009
- By:
- Publication type:
- Article
7
Breast Cancer With a HER2 FISH Group 2 Result: Should HER.2 Tests be Repeated?
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 415, doi. 10.1016/j.clbc.2023.02.006
- By:
- Publication type:
- Article
8
Indocyanine Green and Methylene Blue Dye Guided Sentinel Lymph Node Biopsy in Early Breast Cancer: A Single-Center Retrospective Survival Study in 1574 Patients.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 408, doi. 10.1016/j.clbc.2023.02.002
- By:
- Publication type:
- Article
9
PCDHAl High Expression is Associated With Poor Prognosis and Correlated With Immune Cell Infiltration in Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 397, doi. 10.1016/j.clbc.2023.02.001
- By:
- Publication type:
- Article
10
RANKL Promotes Chemotherapy Resistance in Breast Cancer Cells Through STAT3 Mediated Autophagy Induction.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 388, doi. 10.1016/j.clbc.2023.01.014
- By:
- Publication type:
- Article
11
A Real-World Data Retrospective Cohort Study of HER.2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 378, doi. 10.1016/j.clbc.2023.01.013
- By:
- Publication type:
- Article
12
Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 369, doi. 10.1016/j.clbc.2023.01.012
- By:
- Publication type:
- Article
13
Prospective Clinical Trial on Expanding Indications for Cryosurgery for Early Breast Cancers.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 363, doi. 10.1016/j.clbc.2023.01.007
- By:
- Publication type:
- Article
14
Risk of Recurrence in Patients With HER.2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 350, doi. 10.1016/j.clbc.2023.03.007
- By:
- Publication type:
- Article
15
Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 4, p. 339, doi. 10.1016/j.clbc.2023.02.012
- By:
- Publication type:
- Article